Drugs / JCXH-105
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05871541 | May 2023 → Mar 2024 | herpes zoster | Immorna Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06581575 | Oct 2024 → Aug 2026 overdue | herpes zoster | Immorna Biotherapeutics, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-01-07 | Immorna Biotherapeutics, Inc. | Regulatory 全球首款RNA带状疱疹疫苗JCXH-105获批美国食药监局I期注册临床试验 immorna.com ↗
美国东部时间2023年01月06日，嘉晨西海生物技术有限公司（以下简称“嘉晨西海）宣布，其自主研发的RNA带状疱疹疫苗新药注册临床试验申请 (Investigational New Drug, IND)获得美国食品药品监督管理局 (Food and Drug Administration, FDA)批准进行I 期多中心临床试验。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-01-07 | Immorna Biotherapeutics, Inc. | 全球首款RNA带状疱疹疫苗JCXH-105获批美国食药监局I期注册临床试验 immorna.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JCXH-105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06581575 ↗ |
| Modality | Other / unclassified | “self-replicating (sr) RNA-based vaccine” NCT05871541 ↗ |
| Route | Intramuscular | “As IM injection” NCT05871541 ↗ |